{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:37:03Z","timestamp":1792679823187,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7427","license":[{"start":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T00:00:00Z","timestamp":1349827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/nature11606","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T12:31:36Z","timestamp":1349785896000},"page":"108-112","source":"Crossref","is-referenced-by-count":1632,"title":["EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations"],"prefix":"10.1038","volume":"492","author":[{"given":"Michael T.","family":"McCabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Korenchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Van Aller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Della Pietra","family":"III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsie","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis V.","family":"LaFrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Duquenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan G.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashyant","family":"Dhanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad K.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Tummino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caretha L.","family":"Creasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,10]]},"reference":[{"key":"BFnature11606_CR1","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1126\/science.1165395","volume":"322","author":"S Varambally","year":"2008","unstructured":"Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695\u20131699 (2008)","journal-title":"Science"},{"key":"BFnature11606_CR2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u2013629 (2002)","journal-title":"Nature"},{"key":"BFnature11606_CR3","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606\u201311611 (2003)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature11606_CR4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/1471-2407-10-524","volume":"10","author":"N Wagener","year":"2010","unstructured":"Wagener, N. et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010)","journal-title":"BMC Cancer"},{"key":"BFnature11606_CR5","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1349-7006.2011.01958.x","volume":"102","author":"M Takawa","year":"2011","unstructured":"Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298\u20131305 (2011)","journal-title":"Cancer Sci."},{"key":"BFnature11606_CR6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298\u2013303 (2011)","journal-title":"Nature"},{"key":"BFnature11606_CR7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 42, 181\u2013185 (2010)","journal-title":"Nature Genet."},{"key":"BFnature11606_CR8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genet. 43, 830\u2013837 (2011)","journal-title":"Nature Genet."},{"key":"BFnature11606_CR9","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","volume":"109","author":"MT McCabe","year":"2012","unstructured":"McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989\u20132994 (2012)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature11606_CR10","doi-asserted-by":"crossref","first-page":"e28585","DOI":"10.1371\/journal.pone.0028585","volume":"6","author":"RJ Ryan","year":"2011","unstructured":"Ryan, R. J. et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 6, e28585 (2011)","journal-title":"PLoS ONE"},{"key":"BFnature11606_CR11","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","volume":"107","author":"CJ Sneeringer","year":"2010","unstructured":"Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980\u201320985 (2010)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature11606_CR12","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.febslet.2011.08.018","volume":"585","author":"TJ Wigle","year":"2011","unstructured":"Wigle, T. J. et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 585, 3011\u20133014 (2011)","journal-title":"FEBS Lett."},{"key":"BFnature11606_CR13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","volume":"117","author":"DB Yap","year":"2011","unstructured":"Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451\u20132459 (2011)","journal-title":"Blood"},{"key":"BFnature11606_CR14","doi-asserted-by":"publisher","unstructured":"Diaz, E. et al. Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens. \n                    http:\/\/dx.doi.org\/10.1177\/1087057112453765\n                    \n                   J. Biomol. Screen. (2012)","DOI":"10.1177\/1087057112453765"},{"key":"BFnature11606_CR15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0968-0004(03)00090-2","volume":"28","author":"HL Schubert","year":"2003","unstructured":"Schubert, H. L., Blumenthal, R. M. & Cheng, X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem. Sci. 28, 329\u2013335 (2003)","journal-title":"Trends Biochem. Sci."},{"key":"BFnature11606_CR16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","volume":"8","author":"TB Miranda","year":"2009","unstructured":"Miranda, T. B. et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579\u20131588 (2009)","journal-title":"Mol. Cancer Ther."},{"key":"BFnature11606_CR17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G van Haaften","year":"2009","unstructured":"van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. 41, 521\u2013523 (2009)","journal-title":"Nature Genet."},{"key":"BFnature11606_CR18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood.V75.3.709.709","volume":"75","author":"MJ Dyer","year":"1990","unstructured":"Dyer, M. J., Fischer, P., Nacheva, E., Labastide, W. & Karpas, A. A new human B-cell non-Hodgkin\u2019s lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4;11) chromosomal translocations. Blood 75, 709\u2013714 (1990)","journal-title":"Blood"},{"key":"BFnature11606_CR19","first-page":"1305","volume":"4","author":"AM Al-Katib","year":"1998","unstructured":"Al-Katib, A. M. et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res. 4, 1305\u20131314 (1998)","journal-title":"Clin. Cancer Res."},{"key":"BFnature11606_CR20","first-page":"243","volume":"3","author":"RH Chou","year":"2011","unstructured":"Chou, R. H., Yu, Y. L. & Hung, M. C. The roles of EZH2 in cell lineage commitment. Am. J. Transl. Res. 3, 243\u2013250 (2011)","journal-title":"Am. J. Transl. Res."},{"key":"BFnature11606_CR21","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska, A. M. et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118, 3932\u20133941 (2011)","journal-title":"Blood"},{"key":"BFnature11606_CR22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genet. 42, 722\u2013726 (2010)","journal-title":"Nature Genet."},{"key":"BFnature11606_CR23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","volume":"24","author":"H Makishima","year":"2010","unstructured":"Makishima, H. et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24, 1799\u20131804 (2010)","journal-title":"Leukemia"},{"key":"BFnature11606_CR24","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11606_CR25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693\u20131703 (2010)","journal-title":"N. Engl. J. Med."},{"key":"BFnature11606_CR26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","volume":"43","author":"Y Gui","year":"2011","unstructured":"Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genet. 43, 875\u2013878 (2011)","journal-title":"Nature Genet."},{"key":"BFnature11606_CR27","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2009-10-3-r25","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009)","journal-title":"Genome Biol."},{"key":"BFnature11606_CR28","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/bioinformatics\/btp340","volume":"25","author":"C Zang","year":"2009","unstructured":"Zang, C. et al. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics 25, 1952\u20131958 (2009)","journal-title":"Bioinformatics"},{"key":"BFnature11606_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/abio.1994.1377","volume":"221","author":"K Tornheim","year":"1994","unstructured":"Tornheim, K. Kinetic applications using high substrate and competitive inhibitor concentrations to determine K i or K m . Anal. Biochem. 221, 53\u201356 (1994)","journal-title":"Anal. Biochem."},{"key":"BFnature11606_CR30","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"C Yung-Chi","year":"1973","unstructured":"Yung-Chi, C. & Prusoff, W. H. Relationship between the inhibition constant (K 1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099\u20133108 (1973)","journal-title":"Biochem. Pharmacol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature11606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature11606","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature11606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:06:06Z","timestamp":1684418766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature11606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,10]]},"references-count":30,"journal-issue":{"issue":"7427","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["BFnature11606"],"URL":"https:\/\/doi.org\/10.1038\/nature11606","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717964981.793468872","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,10]]}}}